ELMSFORD, N.Y., Feb. 11, 2014 /PRNewswire/ -- BioScrip ®, Inc. (NASDAQ: BIOS) announced today that the Company will release its 2013 fourth quarter and year-end financial results on Wednesday, February 26, 2014, after the market closes.
The Company will host a conference call at 8:30 a.m. Eastern Standard Time (EST) on Thursday, February 27, 2014. Richard Smith, President and Chief Executive Officer, and Hai Tran, Chief Financial Officer, will conduct the call.
Interested parties may participate in the conference call by dialing 800-616-4018 (US), or 303-223-2680 (International), 5-10 minutes prior to the start of the call. A replay of the conference call will be available for two weeks after the call's completion by dialing 800-633-8284 (US) or 402-977-9140 (International) and entering conference call ID number 21708103. An audio webcast and archive will also be available for 30 days under the "Investor Relations" section of the BioScrip website at www.bioscrip.com.About BioScrip, Inc. BioScrip, Inc. is a leading national provider of infusion and home care solutions. BioScrip partners with physicians, healthcare payors, government agencies, hospital systems and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate- site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by quality, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. BioScrip provides its infusion and home care services from 108 locations across 29 states. SOURCE BioScrip, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts